This is a Validated Antibody Database (VAD) review about rabbit TGFB1, based on 3 published articles (read how Labome selects the articles), using TGFB1 antibody in all methods. It is aimed to help Labome visitors find the most suited TGFB1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
TGFB1 synonym: transforming growth factor beta-1
Abcam
mouse monoclonal (TB21) |
| Abcam TGFB1 antibody (Abcam, ab190503) was used in western blot on mouse samples at 1:500 (fig 4). Int J Mol Med (2016) ncbi |
Invitrogen
mouse monoclonal (TB21) |
| In order to measure TGF-beta, IL-10, and IFN-gamma production by peripheral blood mononuclear cells of unexposed naive subjects and LCL patients after stimulation with live Leishmania guyanensis, Invitrogen TGFB1 antibody (Biosource, TB21) was used in blocking or activating experiments on human samples . Microbes Infect (2007) ncbi |
mouse monoclonal (TB21) |
| In order to show that TGF-beta1 is involved in the suppressive activity of Leishmania guyanensis-stimulated CD4+ CD25+ T cells from healthy controls, Invitrogen TGFB1 antibody (Biosource, TB21) was used in blocking or activating experiments on human samples . Infect Immun (2005) ncbi |
Articles Reviewed
- Bourreau E, Ronet C, Couppie P, Sainte Marie D, Tacchini Cottier F, Launois P. IL-10 producing CD8+ T cells in human infection with Leishmania guyanensis. Microbes Infect. 2007;9:1034-41 pubmed
- Kariminia A, Bourreau E, Pascalis H, Couppie P, Sainte Marie D, Tacchini Cottier F, et al. Transforming growth factor beta 1 production by CD4+ CD25+ regulatory T cells in peripheral blood mononuclear cells from healthy subjects stimulated with Leishmania guyanensis. Infect Immun. 2005;73:5908-14 pubmed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments